Journal of Contemporary Health Law & Policy (1985-2015) Volume 19 Issue 1 Article 6 2002 Botanical Drugs: A Future for Herbal Medicines Weishi Li Follow this and additional works at: https://scholarship.law.edu/jchlp Recommended Citation Weishi Li, Botanical Drugs: A Future for Herbal Medicines, 19 J. Contemp. Health L. & Pol'y 117 (2003). Available at: https://scholarship.law.edu/jchlp/vol19/iss1/6 This Article is brought to you for free and open access by CUA Law Scholarship Repository. It has been accepted for inclusion in Journal of Contemporary Health Law & Policy (1985-2015) by an authorized editor of CUA Law Scholarship Repository. For more information, please contact
[email protected]. BOTANICAL DRUGS: A FUTURE FOR HERBAL MEDICINES Weishi Li* INTRODUCTION In recent years, herbal medicines have attracted strong attention in the United States and worldwide, as part of a larger fascination with natural products. This paper explores the future of herbal medicines in the United States and makes the case that botanical drugs, as a new drug model for herbal medicines, will lend a much-needed arsenal to the perennial fight against human diseases. The current regulatory state of affairs regarding herbal medicines is sub-optimal as it fails to spur rigorous efforts to research and develop effective drugs from herbal medicines. Due to an unfavorable regulatory climate, few U.S. companies engage in developing drug products from herbal medicines. It is argued here that the Food and Drug Administration (FDA) should promote industrial efforts in exploring herbal medicines by approving botanical drugs using a substantially lower regulatory standard.